Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients
© 2022 Society of Hospital Medicine..
BACKGROUND: Statins are a commonly used class of drugs, and reports have suggested that their use may affect COVID-19 disease severity and mortality risk.
OBJECTIVE: The purpose of this analysis was to determine the effect of discontinuation of previous atorvastatin therapy in patients hospitalized for COVID-19 on the risk of mortality and ventilation.
METHODS: Data from 146,413 hospitalized COVID-19 patients were classified according to statin therapy. Home + in hospital atorvastatin use (continuation of therapy); home + no in hospital atorvastatin use (discontinuation of therapy); no home + no in hospital atorvastatin use (no statins). Logistic regression was performed to assess the association between atorvastatin administration and either mortality or use of mechanical ventilation during the encounter.
RESULTS: Continuous use of atorvastatin (home and in hospital) was associated with a 35% reduction in the odds of mortality compared to patients who received atorvastatin at home but not in hospital (odds ratio [OR]: 0.65, 95% confidence interval [CI]: 0.59-0.72, p < .001). Similarly, the odds of ventilation were lower with continuous atorvastatin therapy (OR: 0.70, 95% CI: 0.64-0.77, p < .001).
CONCLUSIONS: Discontinuation of previous atorvastatin therapy is associated with worse outcomes for COVID-19 patients. Providers should consider maintaining existing statin therapy for patients with known or suspected previous use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of hospital medicine - 17(2022), 3 vom: 01. März, Seite 169-175 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andrews, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
A0JWA85V8F |
|---|
| Anmerkungen: |
Date Completed 05.05.2022 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jhm.12789 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340332360 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340332360 | ||
| 003 | DE-627 | ||
| 005 | 20231226004925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jhm.12789 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340332360 | ||
| 035 | |a (NLM)35504528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andrews, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Society of Hospital Medicine. | ||
| 520 | |a BACKGROUND: Statins are a commonly used class of drugs, and reports have suggested that their use may affect COVID-19 disease severity and mortality risk | ||
| 520 | |a OBJECTIVE: The purpose of this analysis was to determine the effect of discontinuation of previous atorvastatin therapy in patients hospitalized for COVID-19 on the risk of mortality and ventilation | ||
| 520 | |a METHODS: Data from 146,413 hospitalized COVID-19 patients were classified according to statin therapy. Home + in hospital atorvastatin use (continuation of therapy); home + no in hospital atorvastatin use (discontinuation of therapy); no home + no in hospital atorvastatin use (no statins). Logistic regression was performed to assess the association between atorvastatin administration and either mortality or use of mechanical ventilation during the encounter | ||
| 520 | |a RESULTS: Continuous use of atorvastatin (home and in hospital) was associated with a 35% reduction in the odds of mortality compared to patients who received atorvastatin at home but not in hospital (odds ratio [OR]: 0.65, 95% confidence interval [CI]: 0.59-0.72, p < .001). Similarly, the odds of ventilation were lower with continuous atorvastatin therapy (OR: 0.70, 95% CI: 0.64-0.77, p < .001) | ||
| 520 | |a CONCLUSIONS: Discontinuation of previous atorvastatin therapy is associated with worse outcomes for COVID-19 patients. Providers should consider maintaining existing statin therapy for patients with known or suspected previous use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Atorvastatin |2 NLM | |
| 650 | 7 | |a A0JWA85V8F |2 NLM | |
| 700 | 1 | |a Goldin, Laurel |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Korwek, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Kleja, Kacie |e verfasserin |4 aut | |
| 700 | 1 | |a Poland, Russell E |e verfasserin |4 aut | |
| 700 | 1 | |a Guy, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Sands, Kenneth E |e verfasserin |4 aut | |
| 700 | 1 | |a Perlin, Jonathan B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hospital medicine |d 2006 |g 17(2022), 3 vom: 01. März, Seite 169-175 |w (DE-627)NLM167663887 |x 1553-5606 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:3 |g day:01 |g month:03 |g pages:169-175 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jhm.12789 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 3 |b 01 |c 03 |h 169-175 | ||